Clinical screening on nondiabetic vaccinated against COVID-19 patients and blood glucose dysregulation levels associated with sars-cov-2 in the post-pandemic period
1 Department of Sciences Medicine, All Lab World Medical Clinic, Presidente Vargas, 529 - Centro, Rio de Janeiro, Brazil.
2 Department of Sciences Veterinary, Clinic Dr. André Luiz, Ramos da Fonseca, 74 - Lins de Vasconcelos, Brazil.
3 Biomedicine, Celso Lisboa University Centre, Rio de Janeiro, Brazil.
4 Department of Health and Agricultural Sciences, Santa Úrsula University, Fernando Ferrari, 75 – Botafogo, Rio de Janeiro, Brazil.
Research Article
International Journal of Frontiers in Biology and Pharmacy Research, 2024, 06(01), 001–006.
Article DOI: 10.53294/ijfbpr.2024.6.1.0036
Publication history:
Received on 29 March 2024; revised on 01 July 2024; accepted on 04 July 2024
Abstract:
Glucose dysregulation in COVID-19 disease has been described in several. Genetic recombination in the viral genome during their replication may be the key role for evolution of viral diseases not yet known. Comparisons between comorbidity patient group and the non-comorbidity patient groups was evaluate to diabetes mellitus (DM) through blood glucose levels collected. This is a retrospective epidemiology study involving patients categorized into three groups according to admission Blood Glucose (BG) levels: < 70 mg/dL; 77 – 90 mg/dL; < 99 mg/dL collected in 2022y. New insulin therapy or increased dosing from baseline had not been considered. The main of this study is to detect the presence of glucose levels in the post-pandemic period, as diabetic people have a higher risk of develop severe illness from COVID-19. From January 2022 to December 2022, 11.019 patients without severe COVID-19 pneumonia were documented. Of these patients, 10004 (90.78 %) were male and 1015 (9.21%) were female. Other predictors factors to comorbidity were not analyzed as pulmonary disease, hypertension, chronic kidney disease, heart failure, and liver cirrhosis. About 11.019 patients who had blood glucose samples collected, 10.004 samples were male gender corresponding to 90.78% while only 1.015 samples corresponding to 9.21% female. However, 89.69% had values within the expected range and 10.25% values above the expected, demonstrating a hyperglycemia index and only 0.054% hypoglycemia was detected in patients collected at the laboratory unit. It has been demonstrated that hyperglycemia in patients with COVID-19 is associated with a higher risk of mortality. So, our study focused on the possibility of vaccinated patients against COVID-19 showed controlled glucose blood levels. In conclusion, our study dataset was a backward-looking study which the glucose parameter listed in the electronic medical records could be analyzed as focuses the predictor factor on vaccinated patients against SARS-CoV-2
Keywords:
SARS-CoV-2; COVID-19; Diabetes; Blood glucose; Risk factor
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0